Examkin

Soru

Zorluk: ZorMonitoring and Treatment Evaluation

A 4545-year-old woman is evaluated in the nephrology clinic for a follow-up appointment. Three years ago, she underwent a deceased-donor renal transplantation for end-stage renal disease secondary to IgA nephropathy. Her maintenance immunosuppressive regimen includes tacrolimus, mycophenolate mofetil, and prednisone. Five days ago, she was evaluated at an urgent care center for fever, cough, and a pulmonary infiltrate on chest radiography, and was prescribed a course of oral clarithromycin for community-acquired pneumonia. Today, she reports that her pulmonary symptoms have improved, but she complains of a new-onset headache and a mild, bilateral hand tremor. Her blood pressure is 158/94158/94 mmHg, which is significantly increased from her baseline of 120/80120/80 mmHg. Physical examination reveals a fine resting tremor in both hands but is otherwise unremarkable. Laboratory studies show a serum creatinine level of 2.32.3 mg/dL; one month ago, it was 1.11.1 mg/dL. Which of the following is the most appropriate next step in the management of this patient?

  1. Measure the serum tacrolimus trough levelCevap
  2. B
    Initiate high-dose intravenous methylprednisolone
  3. C
    Perform a percutaneous renal allograft biopsy
  4. D
    Order a renal duplex ultrasonography
  5. E
    Recommend over-the-counter ibuprofen for the headache and schedule a follow-up appointment

Cevap

The correct answer is to measure the serum tacrolimus trough level.
The most appropriate next step is measuring the serum tacrolimus trough level. Tacrolimus is a calcineurin inhibitor metabolized primarily by the cytochrome P450 3A4 (CYP3A4) enzyme system in the liver and intestines. Clarithromycin, a macrolide antibiotic often prescribed for community-acquired pneumonia, is a potent CYP3A4 inhibitor. Concurrent administration of clarithromycin significantly decreases the clearance of tacrolimus, leading to supratherapeutic, toxic levels. Acute calcineurin inhibitor toxicity classically presents with nephrotoxicity (manifesting as an acute rise in serum creatinine due to intense afferent arteriolar vasoconstriction), new or worsening hypertension, and neurotoxicity (commonly presenting as a fine hand tremor, headache, or in severe cases, seizures). Given that the patient's clinical presentation is highly consistent with tacrolimus toxicity, confirming the elevated trough level is the essential first step to guide subsequent dose reduction and management.

Adım Adım Çözüm

1
Evaluate the patient's new symptoms and laboratory findings in the context of recent medication changes.
The patient has developed acute kidney injury (AKI), new-onset hypertension, and a neurologic symptom (tremor) shortly after starting clarithromycin.
Recognizing the temporal relationship between a new medication and new clinical findings is the first step in diagnosing adverse drug events.
2
Identify the pharmacokinetic interactions of the patient's current medication regimen.
Clarithromycin is a potent inhibitor of the cytochrome P450 3A4 (CYP3A4) enzyme, which is responsible for the hepatic and intestinal metabolism of tacrolimus.
Understanding CYP450 interactions is critical to safely managing patients on narrow-therapeutic-index immunosuppressants.
3
Correlate the clinical presentation with the physiological effects of the identified drug interaction.
Inhibition of CYP3A4 leads to supratherapeutic, toxic levels of tacrolimus. Tacrolimus toxicity classically presents with AKI (via afferent arteriolar vasoconstriction), hypertension, and neurotoxicity (such as tremor and headache).
Confirming that the patient's toxidrome perfectly matches the suspected interaction secures the clinical suspicion and avoids misdiagnosis.
4
Determine the most appropriate next step in monitoring and management.
Obtaining a serum tacrolimus trough level is required to confirm the toxicity and guide subsequent dose reduction.
Establishing the presence of drug toxicity through a non-invasive serum level is the safest and most guideline-concordant approach before pursuing invasive testing.

Anahtar Kavram

Calcineurin inhibitor toxicity secondary to CYP3A4 inhibition requires immediate monitoring of drug trough levels to guide therapeutic adjustment.
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru